Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00464620 · ClinicalTrials.gov registry record · Phase 2
Trial of Dasatinib in Advanced Sarcomas
A Phase 2 study, sponsored by Sarcoma Alliance for Research through Collaboration.
- Completed
- Registry status
- Phase 2
- Development phase
- 366
- Enrollment target
NCT00464620: Completed Phase 2 study, sponsored by Sarcoma Alliance for Research through Collaboration.
NCT00464620 is a Phase 2 study that has completed, run by Sarcoma Alliance for Research through Collaboration. The registered enrollment target is 366 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (175% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00464620, a Phase 2 study, has completed, sponsored by Sarcoma Alliance for Research through Collaboration.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 366 participants
- Enrollment target
Study Summary
This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib.
Primary Outcome
Assessment of objective tumor response for response rate with MRI or CT using Choi criteria: Complete Remission (CR) Complete disappearance of all measurable and evaluable disease for at least 4 weeks; Partial Remission (PR) A 10% or greater decrease from the baseline in the sum of the largest diameters of all measurable target lesions.
Interventions
- DRUG Dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 366 participants |
| Start Date | 2007-05 |
| Est. Completion | 2017-05 |
| Phase | Phase 2 |
What the finished NCT00464620 record still lists
NCT00464620 is an interventional study that assigns participants to a tested intervention. The registered 366 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (175% higher).
The record links to 0 conditions, and to 1 intervention - of which Dasatinib is the first listed.
NCT00464620 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00464620 about?
NCT00464620 is a clinical study titled "Trial of Dasatinib in Advanced Sarcomas". This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib.
What is the current status of trial NCT00464620?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 366 participants. The study started on 2007-05. Estimated completion is 2017-05.
What interventions are being tested in trial NCT00464620?
The interventions under investigation include: Dasatinib (DRUG).
Who is sponsoring clinical trial NCT00464620?
This trial is sponsored by Sarcoma Alliance for Research through Collaboration, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00464620's enrollment target sits among peer trials
366 121st of 2000 higher than 1,880 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05083481 · 366 participants · Phase 1
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
- NCT05429632 · 366 participants · Phase 3
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- NCT06979453 · 366 participants · Phase 3
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
- NCT04049604 · 365 participants · NA
IDENTIFY Study: Natural History of Maternal Neoplasia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia